Key facts
- It has raised $3.5M; the latest was Early Stage VC ($3.5M) in Jan 2026.
- Notable investors include Széchenyi, Development and Innovation Office, National Research, PMK-Group, Vascular Venture.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Novamigra Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Novamigra Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Novamigra Therapeutics
Operator of a biopharmaceutical company intended to develop novel oral therapies that transform migraine prevention and address unmet medical needs. The company offers a first-in-class oral prophylactic treatment with a novel mechanism of action targeting resistant migraine patients, enabling customers to achieve improved quality of life through safer, more effective and accessible migraine prevention services.
- Sector
- Healthcare
- HQ
- Budapest, Hungary
- Founded
- 2025
- Website
- novamigratherapeutics.com/
- Ownership
- Privately Held (backing)
Novamigra Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Novamigra Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Novamigra Therapeutics in its N-PORT filings yet. We sweep new filings monthly.